Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00978042 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation
A NA study of Mid-facial Volume Deficit Related to Aging, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 345
- Enrollment target
- 2
- Study locations
NCT00978042 is a NA study of Mid-facial Volume Deficit Related to Aging that has completed, run by Allergan. The registered enrollment target is 345 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00978042, a NA study of Mid-facial Volume Deficit Related to Aging, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 345 participants
- Enrollment target
- 2
- Study locations
Study Summary
Multicenter, single-blind, randomized, "no-treatment" control study to demonstrate the safety and effectiveness of VOLUMA XC for deep injection for cheek augmentation to correct age-related volume deficit in the mid-face.
Conditions Studied
Interventions
- DEVICE Juvéderm® VOLUMA XC
Study Locations (2)
California
- - Los Angeles
British Columbia
- - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2009-08 |
| Est. Completion | 2014-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00978042
The ClinicalTrials.gov registry entry for NCT00978042 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mid-facial Volume Deficit Related to Aging appearing as the primary indexed condition, and to 1 intervention - of which Juvéderm® VOLUMA XC is the first listed.
NCT00978042 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, British Columbia.
Frequently Asked Questions
What is clinical trial NCT00978042 about?
NCT00978042 is a clinical study titled "Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation". Multicenter, single-blind, randomized, "no-treatment" control study to demonstrate the safety and effectiveness of VOLUMA XC for deep injection for cheek augmentation to correct age-related volume deficit in the mid-face.
What is the current status of trial NCT00978042?
This trial is currently completed. It is a NA study. The enrollment target is 345 participants. The study started on 2009-08. Estimated completion is 2014-04.
What conditions does trial NCT00978042 study?
This clinical trial studies the following conditions: Mid-facial Volume Deficit Related to Aging.
What interventions are being tested in trial NCT00978042?
The interventions under investigation include: Juvéderm® VOLUMA XC (DEVICE).
Who is sponsoring clinical trial NCT00978042?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00978042 being conducted?
This trial has 2 study locations across California, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.